Nektar Therapeutics
- NKTR
- NASDAQ
- Biotechnology
- Immuno-Oncology (IL-2 Agonist)
- Biopharmaceutical Pipeline
- Cancer Therapeutics
$35.78
Today −5.14%Quote Oct 16, 2026, 08:00 PM UTC
−47.66%over the last month
Max drawdown −47.7%From 1-month high −47.7%3 months −44.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.22B
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$130.43
+264.5% from here
Floor
$33.53
6.3% below price
Where the price sits
33 analysts
Analyst range, low to high
$50.00$192.00
- Price $35.78
- Resistance $35.99
- Consensus $130.43
The price is right under resistance. Analysts' average target sits about 265% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NKTRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
63